Moffitt Cancer Center researcher tests BPC-157 for chemotherapy muscle loss
Dr. Vincent Luca told WFLA that rigorous testing of peptide function is lacking, even as BPC-157 heads toward FDA reclassification for pharmacy compounding.
PR
By Priya Raman · Science Reporter
Sep 22 23:10 ETSource: AOL.com
The wire
- 01Moffitt Cancer Center's Vincent Luca said his team is testing BPC-157, citing possible use in regenerating muscle mass lost during chemotherapy.
- 02BPC-157 is one of six peptides expected to be reclassified by the FDA to allow pharmacy compounding, a change publicly backed by HHS Secretary Robert F. Kennedy Jr.
- 03Luca said long-term studies are missing for BPC-157 and many other peptides; no results, timeline or study design were disclosed in the broadcast report.
From the source
Read at aol.comFad or the future? Weighing the pros and cons of peptides
TAMPA, Fla. (WFLA) -- A fad or the future? Peptides is overwhelmingly one of the most talked about topics in the health community right now. It's also one of the most argued.
